Herantis Pharma Oyj
HRTIS.HE
Get informed when a big investor buys or sells
+ FollowMarket Cap$59.47M
Close$
Share Statistics
| Market cap | $59.47 Million |
|---|---|
| Enterprise Value | $62.17 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.28 |
| Beta | 0.63 |
| Outstanding Shares | 25,872,751 |
Return
| Return on Equity | 1532.29% |
|---|---|
| Return on Assets | -302.06% |
| Return on Invested Capital | -443.26% |
Valuation & Multiples
| P/E Ratio | -4.97 |
|---|---|
| PEG | -129.35 |
| Price to Sales | - |
| Price to Book Ratio | -1.34 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -5.31 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | -4.33 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 4, 2027
EPS Estimate
$-0.07
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Herantis Pharma Oyj
14 employees
CEO: Antti Vuolanto Herantis Pharma Oyj, a biotechnology company founded in Espoo, Finland, in 2008, is dedicated to developing innovative, disease-modifying CDNF-based treatments for Parkinson's disease (PD). Its pipeline features two key assets: HER-096, ...